BioCryst Pharmaceuticals logo

BioCryst PharmaceuticalsNASDAQ: BCRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 March 1994

Next earnings report:

26 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.45 B
-60%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
0%vs. 3y high
12%vs. sector
-84%vs. 3y high
53%vs. sector

Price

after hours | Fri, 15 Nov 2024 23:37:51 GMT
$7.02-$0.58(-7.63%)

Dividend

No data over the past 3 years
$117.08 M$124.17 M
$117.08 M-$14.03 M

Analysts recommendations

Institutional Ownership

BCRX Latest News

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: NEUTRAL

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Jinky Rosselli - Chief Data and Insights Officer Conference Call Participants Nick Lenard - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Stacy Ku - TD Cowen Liisa Bayko - Evercore ISI Gena Wang - Barclays Serge Belanger - Needham & Company Operator Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com04 November 2024 Sentiment: POSITIVE

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

BioCryst (BCRX) Upgraded to Buy: Here's Why
zacks.com07 October 2024 Sentiment: POSITIVE

BioCryst (BCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
zacks.com05 August 2024 Sentiment: POSITIVE

The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com05 August 2024 Sentiment: POSITIVE

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com05 August 2024 Sentiment: POSITIVE

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
zacks.com29 July 2024 Sentiment: NEGATIVE

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
seekingalpha.com21 July 2024 Sentiment: POSITIVE

BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
zacks.com18 July 2024 Sentiment: POSITIVE

BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
The Motley Fool06 May 2024 Sentiment: POSITIVE

The company announced its first-quarter earnings that morning, achieving strong results in both revenue and profit.

  • 1(current)

What type of business is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

What sector is BioCryst Pharmaceuticals in?

BioCryst Pharmaceuticals is in the Healthcare sector

What industry is BioCryst Pharmaceuticals in?

BioCryst Pharmaceuticals is in the Biotechnology industry

What country is BioCryst Pharmaceuticals from?

BioCryst Pharmaceuticals is headquartered in United States

When did BioCryst Pharmaceuticals go public?

BioCryst Pharmaceuticals initial public offering (IPO) was on 04 March 1994

What is BioCryst Pharmaceuticals website?

https://www.biocryst.com

Is BioCryst Pharmaceuticals in the S&P 500?

No, BioCryst Pharmaceuticals is not included in the S&P 500 index

Is BioCryst Pharmaceuticals in the NASDAQ 100?

No, BioCryst Pharmaceuticals is not included in the NASDAQ 100 index

Is BioCryst Pharmaceuticals in the Dow Jones?

No, BioCryst Pharmaceuticals is not included in the Dow Jones index

When was BioCryst Pharmaceuticals the previous earnings report?

No data

When does BioCryst Pharmaceuticals earnings report?

The next expected earnings date for BioCryst Pharmaceuticals is 26 February 2025